Cognition Therapeutics Receives End-of-Phase 2 Meeting Minutes Confirming Alignment with U.S. FDA on Registrational Path for Zervimesine (CT1812) in Alzheimerâs Disease
- Cognition and FDA align on enriched population, study design, and endpoints -